Pregnancy and Multiple Sclerosis

 

 Buy Article Permissions and Reprints

ABSTRACT

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system affecting predominantly women of childbearing age; therefore, issues of conception, pregnancy, and delivery become of significant importance to patients and treating physicians. This article discusses the immunological and clinical effects of pregnancy on the course of MS, clinical outcomes of Pregnancy in Multiple Sclerosis (PRIMS) trials, the available data on safety and efficacy of immunomodulating MS treatments and symptomatic treatments for pregnant and lactating women, and specific issues of MS management at the time of pregnancy. The data related to estrogen-based MS therapies currently or previously in trials are reviewed. Pregnancy does not appear to be associated with adverse outcomes in MS patients. Some evidence suggests possible beneficial effects, although clear prospective data of sufficient length are limited. Long-term relapse rates and disability progression do not seem to be affected by pregnancy in MS patients. The use of immunosuppressive or immunomodulatory agents in pregnancy is not routinely advisable.

REFERENCES

• 1 Douglass L H, Jorgensen C L. Pregnancy and multiple sclerosis.  Am J Obstet Gynecol. 1948;  55 332-336
  PubMedGoogle Scholar
• 2 Confavreux C, Hutchinson M, Hours M, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis.  N Engl J Med. 1998;  339 285-291
  CrossrefPubMedGoogle Scholar
• 3 Vukusic S, Hutchinson M, Hours M et al.. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.  Brain. 2004;  127 1353-1360
  CrossrefPubMedGoogle Scholar
• 4 Rossouw J E, Anderson G L, Prentice R L et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial.  JAMA. 2002;  288 321-333
  CrossrefPubMedGoogle Scholar
• 5 Thorogood M, Hannaford P C. The influence of oral contraceptives on the risk of multiple sclerosis.  Br J Obstet Gynaecol. 1998;  105 1296-1299
  CrossrefPubMedGoogle Scholar
• 6 Alonso A, Jick S S, Olek M J, Ascherio A, Jick H, Hernán M A. Recent use of oral contraceptives and the risk of multiple sclerosis.  Arch Neurol. 2005;  62 1362-1365
  CrossrefPubMedGoogle Scholar
• 7 Dwosh E, Guimond C, Sadovnick A D. Reproductive counselling for MS: a rationale.  Int MS J. 2003;  10 52-59
  PubMedGoogle Scholar
• 8 Zorzon M, Zivadinov R, Bosco A et al.. Sexual dysfunction in multiple sclerosis: a case-control study. Frequency and comparison of groups.  Mult Scler. 1999;  5 418-427
  PubMedGoogle Scholar
• 9 Hughes M D. Multiple sclerosis and pregnancy.  Neurol Clin. 2004;  22 757-769
  CrossrefPubMedGoogle Scholar
• 10 Sadovnick A D, Baird P A, Ward R H. Multiple sclerosis: updated risks for relatives.  Am J Med Genet. 1988;  29 533-541
  CrossrefPubMedGoogle Scholar
• 11 Hunt J S. Immunobiology of pregnancy.  Curr Opin Immunol. 1992;  4 591-596
  CrossrefPubMedGoogle Scholar
• 12 Damek D M, Shuster E A. Pregnancy and multiple sclerosis.  Mayo Clin Proc. 1997;  72 977-989
  PubMedGoogle Scholar
• 13 Athanasas-Platsis S, Zhang B, Hillyard N C et al.. Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis.  J Neurol Sci. 2003;  214 27-36
  CrossrefPubMedGoogle Scholar
• 14 Drew P D, Chavis J A. Female sex steroids: effects upon microglial cell activation.  J Neuroimmunol. 2000;  111 77-85
  CrossrefPubMedGoogle Scholar
• 15 Gilmore W, Arias M, Stroud N, Stek A, McCarthy K A, Correale J. Preliminary studies of cytokine secretion patterns associated with pregnancy in MS patients.  J Neurol Sci. 2004;  224 69-76
  CrossrefPubMedGoogle Scholar
• 16 Abramsky O, Brenner T, Mirzachi R, Soffer D. Alpha-fetoprotein suppresses experimental allergic encephalomyelitis.  J Neuroimmunol. 1982;  2 1-7
  CrossrefPubMedGoogle Scholar
• 17 Altman D J, Schneider S L, Thompson D A, Cheng H L, Tomasi T B. A transforming growth factor beta 2 (TGF-beta-2)-like immunosuppressive factor in amniotic fluid and localization of TGF-beta 2 mRNA in the pregnant uterus.  J Exp Med. 1990;  172 1391-1401
  CrossrefPubMedGoogle Scholar
• 18 Correale J, Gilmore W, McMillan M et al.. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T lymphocytes.  J Immunol. 1995;  154 2959-2968
  PubMedGoogle Scholar
• 19 Byrnes A A, McArthur J C, Karp C L. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin 10 production.  Ann Neurol. 2002;  51 165-174
  CrossrefPubMedGoogle Scholar
• 20 López C, Comabellaa M, Tintoré M, Sastre-Garriga J. X Montalban X. Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients.  Mult Scler. 2006;  12 421-427
  CrossrefPubMedGoogle Scholar
• 21 Saraste M, Ryynänen J, Alanen J et al.. Cerebrospinal fluid findings in multiple sclerosis patients before, during and after pregnancy.  J Neurol Neurosurg Psychiatry. 2006;  77 1195-1196
  CrossrefPubMedGoogle Scholar
• 22 Weinshenker B G, Bass B, Rice G P et al.. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.  Brain. 1989;  112 133-146
  CrossrefPubMedGoogle Scholar
• 23 Frith J A, Mcleod J G. Pregnancy and multiple sclerosis.  J Neurol Neurosurg Psychiatry. 1988;  51 495-498
  PubMedGoogle Scholar
• 24 Birk K, Ford C, Smeltzer S et al.. The clinical course of multiple sclerosis during pregnancy and the puerperium.  Arch Neurol. 1990;  47 738-742
  CrossrefPubMedGoogle Scholar
• 25 Vukusic S, Confavreux C. Pregnancy and multiple sclerosis: The children of PRIMS.  Clin Neurol Neurosurg. 2006;  108 266-270
  CrossrefPubMedGoogle Scholar
• 26 Kurtzke J F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS).  Neurology. 1983;  33 1444-1452
  CrossrefPubMedGoogle Scholar
• 27 Salemi G, Callari G, Gammino M et al.. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study.  Acta Neurol Scand. 2004;  110 23-26
  CrossrefPubMedGoogle Scholar
• 28 Runmarker B, Anderson O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis.  Brain. 1995;  118 253-261
  CrossrefPubMedGoogle Scholar
• 29 Stenager E, Stenager E N, Jensen K. Effect of pregnancy on the prognosis for multiple sclerosis. A 5-year follow up investigation.  Acta Neurol Scand. 1994;  90 305-308
  PubMedGoogle Scholar
• 30 Mueller B A, Zhang J, Critchlow C W. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis.  Am J Obstet Gynecol. 2002;  186 446-452
  CrossrefPubMedGoogle Scholar
• 31 Worthington J, Jones R, Crawford M et al.. Pregnancy and multiple sclerosis: a 3-year prospective study.  J Neurol. 1994;  241 228-233
  CrossrefPubMedGoogle Scholar
• 32 Dahl J, Myhr K M, Daltveit A K, Hoff J M, Gilhus N E. Pregnancy, delivery, and birth outcome in women with multiple sclerosis.  Neurology. 2005;  65 1961-1963
  CrossrefPubMedGoogle Scholar
• 33 de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis.  Mult Scler. 2004;  10 596-597
  CrossrefPubMedGoogle Scholar
• 34 Janssen N M, Genta S G. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation.  Arch Intern Med. 2000;  160 610-619
  PubMedGoogle Scholar
• 35 Penn I, Makowski E, Droegemueller W, Halgrimson C G, Starzl T E. Parenthood in renal transplant recipients.  JAMA. 1971;  216 1755-1761
  CrossrefPubMedGoogle Scholar
• 36 Kozlowski R D, Steinbrunner J V, McKenzie A H, Clough J D, Wilke W S, Segal A M. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease.  Am J Med. 1990;  88 589-592
  CrossrefPubMedGoogle Scholar
• 37 Nguyen C, Duhl A J, Excallon C S, Blakemore K J. Multiple anomalies in a fetus exposed to a low-dose methotrexate in the first trimester of pregnancy.  Obstet Gynecol. 2002;  99 599-602
  CrossrefPubMedGoogle Scholar
• 38 Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis.  Transplantation. 2001;  71 1051-1055
  CrossrefPubMedGoogle Scholar
• 39 Walther E U, Hohlfeld R. Multiple sclerosis: side-effects of interferon beta therapy and their management.  Neurology. 1999;  53 1622-1627
  CrossrefPubMedGoogle Scholar
• 40 Coyle P K, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate. In: Proceedings of the 55th Annual Meeting of the American Academy of Neurology.  Neurology. 2003;  60(suppl 1) A60
  PubMedGoogle Scholar
• 41 Boskovic R, Wide R, Wolpin J, Bauer D J, Koren G. The reproductive effects of beta interferon therapy in pregnancy. a longitudinal cohort.  Neurology. 2005;  65 807-811
  CrossrefPubMedGoogle Scholar
• 42 Waubant E, Sadovnick A D. Interferon beta babies.  Neurology. 2005;  65 788-789
  CrossrefPubMedGoogle Scholar
• 43 Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of child-birth-associated acute exacerbations in multiple sclerosis: a pilot study.  J Neurol. 1996;  243 25-28
  PubMedGoogle Scholar
• 44 Van Walderveen M AA, Tas M W, Barkhof F. Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis.  Neurology. 1994;  44 327-329
  PubMedGoogle Scholar
• 45 Voskuhl R R, Palaszynski K. Sex hormones and experimental autoimmune encephalomyelitis: implications for multiple sclerosis.  Neuroscientist. 2001;  7 258-270
  PubMedGoogle Scholar
• 46 Jansson L, Olsson T, Holmdahl R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice.  J Neuroimmunol. 1994;  53 203-207
  CrossrefPubMedGoogle Scholar
• 47 Sicotte N L, Liva S M, Klutch R et al.. Treatment of multiple sclerosis with the pregnancy hormone estriol.  Ann Neurol. 2002;  52 421-428
  CrossrefPubMedGoogle Scholar
• 48 Rizvi S A, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis.  Neurology. 2004;  63(suppl 6) S47-S54
  PubMedGoogle Scholar

Maria K HoutchensM.D. M.Sc. 

Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School

1 Brookline Place, #225, Brookline, MA 02445

Email: mhoutchens@partners.org